Novartis AG (NOVN.SW) Stock Analysis & Winston Score

Novartis is a Swiss pharmaceutical company that discovers, makes, and sells prescription medicines to patients around the world. Its key products include Cosentyx for autoimmune diseases, Entresto for heart failure, and Kisqali for breast cancer, with hospitals, doctors, and pharmacies as its main customers. It is one of the largest drug companies in the world by revenue and market value. Novartis makes money primarily by selling branded prescription drugs, which are protected by patents that allow the company to charge premium prices. It operates globally, with strong sales across the United States, Europe, and emerging markets, generating roughly $45 billion in annual revenue. The company's main competitive advantage is its large portfolio of patented medicines and its deep research pipeline, but its biggest ongoing risk is patent expiration — when patents run out, cheaper generic versions enter the market and can sharply reduce revenue from those drugs.